Montelukast Normon

Montelukast, the active ingredient in Montelukast Normon, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, exercise‑induced bronchoconstriction, and allergic rhinitis in adults and children as directed by a healthcare professional.

GNH USA supplies Montelukast Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality assurance processes and regulatory compliance across EU and global markets. The company ensures reliable delivery timelines and supports pharmacovigilance reporting for its customers.

Montelukast is a leukotriene receptor antagonist used to treat conditions mediated by leukotriene‑driven inflammation. - Asthma: reduces frequency of wheezing episodes and improves lung function in patients with persistent asthma. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate headache reported in clinical use. - Abdominal pain: occasional stomach discomfort or cramps. - Nausea: transient feeling of queasiness. - Dizziness: light‑headed sensation, especially after first doses. - Cough: mild, non‑productive cough. - Sore throat: irritation of the throat.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis requiring immediate medical attention. - Mood changes: reports of agitation, depression or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests in rare cases. - Stevens‑Johnson syndrome: severe skin reactions. - Eosinophilic granulomatosis with polyangiitis: rare vasculitic disorder.

When prescribing Montelukast, consider the following safety measures. - Pregnancy: Category B – use only if clearly needed after risk‑benefit assessment. - Breastfeeding: weigh potential infant exposure against maternal benefit. - Pediatric use: safety established in children six months of age and older; monitor growth. - Drug interactions: review concomitant medications for possible pharmacokinetic effects. - Renal/hepatic impairment: use with caution in severe dysfunction and monitor clinical response. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Montelukast may interact with several medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Ritonavir: potent CYP3A4 inhibitor that can raise montelukast levels. - Phenobarbital, carbamazepine, phenytoin: strong enzyme inducers that may reduce efficacy. - Fluconazole: may increase systemic exposure.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR; monitor coagulation parameters. - Beta‑agonists: additive bronchodilator effect; observe for excessive stimulation. - ACE inhibitors: monitor for heightened cough or angioedema risk.